NCT05581342View on ClinicalTrials.gov

Added Value of OCT for Diagnosing Recurrent BCC After Non-invasive Treatment

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions
Basal Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

Punch biopsy (3mm)

In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.

Trial Locations (1)

6202AZ

Maastricht University Medical Center+, Maastricht

All Listed Sponsors
lead

Maastricht University Medical Center

OTHER

NCT05581342 - Added Value of OCT for Diagnosing Recurrent BCC After Non-invasive Treatment | Biotech Hunter | Biotech Hunter